We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

HealthBox

Status: Extended

Dec 1st 2020 - Jan 4th 2021

HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

read more read less

HealthBox Rating Review

Pitch rating powered by CROWDRATING

Rated on 30/12/2020

Pitch Rated

79%

overall

Management

80%

Product

74%

Investment

82%

Log in to view amount pledged

    Log in to view target

    £3,127,928
    pre-money valuation

    3.69%
    equity available

    145
    investors

    £995
    pledge per investor

    12485469
    company number

    Active
    company status

    26/02/2020
    incorporated 4 years

    Previous Funding rounds
    27 Mar 24 Seedrs £144,265 / 120% 78.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 80%

Skills 82%
HealthBox is led by a team of serial entrepreneurs, professionals, and industry experts in technical, marketing, and finance. The Founder/Director is skilled in strategic planning, project management, market research, building relationships, market planning, and cloud computing. The Finance Director has expertise in Budgeting, Business Planning, Accounting, Customer Relationship Management (CRM), and Taxation. The Executive Assistant Director is skilled in Google, Microsoft, Customer Service, Customer Relationship Management (CRM), and Event Management. The Development Team Lead is an experienced web developer, and he is skilled in PHP, Zend Framework, LAMP, Web, and Application designing. The Head of Sales and the Head Of Corporate Strategy lead to developing strategic plans and objectives by identifying opportunities that will influence business growth and profitability. Their roles and responsibilities include the marketing program, industry intelligence, consumer knowledge, and strategic initiatives development. They also lead the high-priority objectives, working directly with the founder/director to support the company's overall performance.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £3,127,928
    pre-money valuation

    3.69%
    equity available

    145
    investors

    £995
    pledge per investor

    12485469
    company number

    Active
    company status

    26/02/2020
    incorporated 4 years

    Previous Funding rounds
    28 Mar 24 Seedrs £144,265 / 120% 78.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph